Primary Sjögren's syndrome-associated immune thrombocytopenia: from pathogenesis to treatment - PubMed
5 hours ago
- #autoimmune disorder
- #treatment strategies
- #immune thrombocytopenia
- Primary Sjögren's syndrome (pSS) is an autoimmune disorder causing dry mouth and eyes, with 10%-20% of patients developing immune thrombocytopenia (ITP).
- Pathogenesis of pSS-ITP may involve dysregulated TLR7 signaling, B-cell hyperactivation, and autoantibody-mediated platelet destruction.
- Emerging treatments include thrombopoietin receptor agonists (TPO-RAs), B-cell-targeted therapies, and mTOR inhibitors.
- Predictive models using bone marrow megakaryocyte counts and autoantibody profiles may help in individualized treatment selection.
- Future studies are needed to evaluate long-term efficacy and safety of novel treatments and explore biomarker-guided precision therapy.